Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma.

Ya-Hsuan ChangChih-Hsiang YuMeng-Yao LuShiann-Tarng JouChien-Yu LinKai-Hsin LinHsiu-Hao ChangYu-Ling NiShu-Wei ChouKuan-Yin KoDong-Tsamn LinWen-Ming HsuHsuan-Yu ChenYung-Li Yang

Published in: Pediatric blood & cancer (2024)

Genome sequencing to determine the tumor mutational burden and ALK variations can improve the risk classification of neuroblastoma and inform treatment.

Keyphrases

machine learning
risk factors
single cell
gene expression
genome wide
dna methylation
tyrosine kinase